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Abstract 34 
Leishmaniasis represents a group of parasitic diseases caused by protozoan of the genus 35 
Leishmania and is widely distributed in tropical and subtropical regions. Leishmaniasis is one of 36 
the major tropical neglected diseases, with 1.5-2 million new cases occurring annually. Diagnosis 37 
remains a challenge despite advances in parasitological, serological and molecular methods.  38 
Dogs are important host for the parasite and develop both visceral and cutaneous lesions. Our 39 
goal was to contribute to the diagnosis of canine cutaneous leishmaniasis (CL) and visceral 40 
leishmaniasis (VL) using the recombinant cysteine proteinase B (F-CPB) from Leishmania 41 
braziliensis and its N- and C-terminal domains (N-CPB and C-CPB) as antigens in an ELISA 42 
assay. Sera of dogs from the Northwest Argentina diagnosed with CL were tested by ELISA 43 
against a supernatant of L. braziliensis lysate, the F-CPB protein and its domains. We found values 44 
of sensitivity (Se) of 90.7, 94.4 and 94.3 % and specificity (Sp) of 95.5, 90.9 and 91.3% for F-CPB 45 
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and its N- and C-terminal domains, respectively. In dog sera from Northeast Argentina diagnosed 46 
with VL we found Se of 93.3, 73.3 and 66.7 and Sp of 92.3, 76.9 and 88.5 for F-CPB and its N- 47 
and C-terminal domains. These results support CPB as a relevant antigen for canine leishmaniasis 48 
diagnosis in its different clinical presentations. More interestingly, the amino acid sequence of 49 
CPB showed high percentages of identity in several Leishmania species, suggesting that the CPB 50 
from L. braziliensis qualifies as a good antigen for the diagnosis of leishmaniasis caused by 51 
different species.  52 
 53 
Introduction  54 
Leishmaniasis is endemic in 88 countries, with an estimated 350 million people at risk of 55 
becoming infected. Leishmaniasis is transmitted by the bite of infected female phlebotomine 56 
sandflies and is caused by different flagellate protozoans of the family Trypanosomatidae 57 
belonging to the genus Leishmania (1). These intracellular protozoa have a complex digenetic life 58 
cycle, requiring a susceptible vertebrate host and a permissive insect vector, which allow their 59 
transmission. The main epidemiological reservoirs of Leishmania infantum are dogs, which can 60 
remain asymptomatic for long periods of time, to finally develop cutaneous or systemic symptoms 61 
(2, 3). In Latin America, canine leishmaniasis is widespread, being one of the most important 62 
canine zoonotic vector-borne diseases (4).  63 
More than 20 species and subspecies of Leishmania infect humans and dogs causing a wide 64 
spectrum of diseases, ranging from: cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis 65 
(MCL), diffuse cutaneous leishmaniasis (DCL) and visceral leishmaniasis (VL), depending on the 66 
parasite virulence factors and the immune response established by the host (5). In America, CL, 67 
MCL, and DCL taken together are also known as American tegumentary leishmaniasis (TL), with 68 
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a wide geographical distribution from Southern United States to Northern Argentina. In 69 
Northwestern Argentina (NWA) there have been several CL outbreaks, mainly in the forest of 70 
Salta (6,7). 71 
In 2006 the first autochthonous human VL case was reported in Posadas, province of Misiones 72 
(Northeastern Argentina, NEA) (8, 9). Since then, climate change has contributed to the spread of 73 
VL in Argentina. Dogs have been found to be naturally infected with species such as Leishmania 74 
(Viannia) peruviana, L. (Leishmania) major, and L. (L.) tropica, among others, in several countries 75 
(10). In Argentina, L. (V.) braziliensis and L. (L.) infantum have been incriminated as the causal 76 
agents of canine leishmaniasis in the cities of Orán and Posadas, NWA and NEA, respectively (11, 77 
12, 13).  78 
Traditionally, the diagnosis of leishmaniasis is based on the microscopic detection of 79 
amastigotes in tissue macrophages obtained by aspiration, scraping, or skin biopsy for CL, and in 80 
bone marrow, nodes and spleen for VL. However, the presence of amastigotes depends on several 81 
factors, and they can be morphologically misidentified as fungi, Toxoplasma, Histoplasma or even 82 
artifacts (14). In order to increase diagnostic sensitivity and specificity, cultured lesion material 83 
and molecular biology techniques such as PCR and real-time PCR (qPCR) have been proposed 84 
(15, 16). However, not all Leishmania strains grow at the same rate and not all tissues have a 85 
similar parasite load. Moreover, these techniques are expensive and require sophisticated 86 
laboratories.  87 
As VL infection develops, large amounts of polyclonal antibodies are produced in the host 88 
(hypergammaglobulinemia). Therefore, various methods of detection of non-specific antibodies 89 
have been used, which have subsequently been discarded for lack of sensitivity and specificity. 90 
Other methods such as electrophoresis, hemagglutination, complement fixation test and gel 91 
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diffusion test have been performed in different endemic areas. Currently, only the direct 92 
agglutination test, the immunofluorescent antibody test (IFAT), ELISA and 93 
immunochromatography are being used (17-19). Improving serological tests for the diagnosis of 94 
leishmaniasis is important because they are rapid, easy to perform and can be easily implemented 95 
under the conditions commonly encountered in developing countries. 96 
 Antibodies against a wide range of parasitic antigens such as rK39 (a kinesin-related antigen), 97 
rK9 and rK26, heat shock proteins (HSP-70), histones (H-2A, 2B-H, H-3 and H-4), cysteine 98 
proteinases (CPA and CPB), gp63 and gp70 proteins, ribosomal proteins P (P0, P2a, P2b), iron- 99 
superoxide dismutases (Fe-SODe) and the cathepsin L-like protein, among others, have been 100 
detected in Leishmania spp. infection (20-23). The rK39 antigen is one of the most used antigens 101 
for the diagnosis of canine and human VL, showing excellent results mainly in India, where 102 
sensitivity and specificity are almost 100% (24-28). Although antigen rK39 has been important for 103 
VL serodiagnosis, it does not allow the diagnosis of CL or MCL (29-30). 104 
The identification of new antigens to be employed in sensitive and specific serological assays 105 
is highly desirable. Extensive studies on the parasitic protozoan Leishmania have shown that 106 
cysteine proteinases (CPs) are involved in parasite survival, replication and the onset of disease 107 
(31). The cysteine proteinase B (CPB) from Leishmania spp. is present in all strains and stages of 108 
the parasite and plays a crucial role in host-parasite interaction. The genes that code for the CPBs 109 
in trypanosomatids are organized as follows: a pre-region, a propeptide, the catalytic domain, and 110 
a C-terminal extension (32, 33). The latter, as those of other CP orthologues, presents different 111 
immunogenic properties. We have demonstrated that the immune response in T. cruzi infection is 112 
directed mostly against the C-terminal domain (34). This part of the antigen may operate as a 113 
diversion of the immune system, concentrating the antibody response against the C-terminal 114 
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domain, and preserving the enzymatic activity of the N-terminal domain. Accordingly, our overall 115 
objective was to contribute to the diagnosis of cutaneous and visceral leishmaniasis in dogs using 116 
the recombinant CPB from L. braziliensis and its domains for the detection of specific antibodies 117 
against Leishmania spp.  118 
 119 
Materials and methods 120 
Cloning, expression and purification of CPB and its domains in prokaryotic cells. 121 
The cloning of the recombinant proteins will be described elsewhere (Bivona AE, unpublished 122 
results). Briefly, the CPB gene of L. braziliensis (LbrM08_V2.0820, accession XM_001562090) 123 
was synthesized by GenScript, optimizing the sequence between nucleotides 373 to 954 for 124 
expression in prokaryotic cells. From this gene, using specific primers containing cleavage sites 125 
for restriction enzymes and a tail of six histidines, we synthesized by PCR sequences of 954, 657 126 
and 297 bp corresponding to the full length CPB and its N-and C- terminal domains, respectively. 127 
The purified PCR products were digested with restriction enzymes and ligated to plasmid pET23a. 128 
Bacterium Escherichia coli DH5 was transformed with the constructs and after selecting positive 129 
clones for their resistance to ampicillin, the presence of the inserts was confirmed by digestion 130 
with restriction enzymes. Constructs showed at least 97% identity with the previously reported 131 
sequence (LbrM08_V2.0820) for the entire CPB and N- and C-terminal domains. 132 
The resulting vectors were then transformed into E. coli BL21 (DE3) cells for expression. 133 
Recombinant proteins were obtained by inducing bacterial cultures with 1mM isopropyl-L-thio-β-134 
D-galactoside (IPTG) for 4 h. Cells were harvested, centrifuged, and resuspended in lysis buffer 135 
pH 8.0 containing 100 mM NaH2PO4, 10 mM Tris-HCl, 8 M urea, 1 mM PMSF, 1 µM E-64. The 136 
cells were stirred at room temperature for 60 min and then centrifuged at 10,000 ×g for 20 min to 137 
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pellet the cell debris. Proteins were purified under denaturing conditions from the supernatant 138 
using a Ni2+-nitrilotriacetic acid-Sepharose matrix. Properly folded proteins were obtained by 139 
extensive dialysis against buffer 2 M urea, 50 mM Tris, 5% sucrose, 10% glycerol, 0.3 M NaCl, 140 
0.5 mM EDTA followed by dialysis in phosphate-buffered saline (PBS)-20% glycerol and stored 141 
at -70°C until use. Protein concentration was determined by the Bradford protein assay (Bio-Rad, 142 
Hercules, CA), using bovine serum albumin (Sigma) as a standard.  143 
 144 
Dog serum samples  145 
Study 1: Samples were taken in the localities of Colonia Santa Rosa, Pichanal and Orán, 146 
Province of Salta, NWA. The study area is included within the biogeographic “Yungas” rainforest 147 
(6). The Province of Salta has been the area of Argentina with high incidence of CL, with most 148 
cases originating in the Orán Department (7, 35, 36). Moreover, L. braziliensis has been 149 
acknowledged as   the main causative agent for CL in this area of Argentina (7, 35). 150 
Samples stored at -20°C, were collected from 76 dogs previously diagnosed with leishmaniasis 151 
by the identification of amastigotes in Giemsa-stained material obtained by touch print, scraping, 152 
exudate, or aspirate obtained by injecting 0.1–0.4 ml of buffered saline solution plus penicillin-153 
streptomycin followed by an aspirate of the fluid (6). Clinical signs support the diagnosis of CL 154 
(6, 37). The entire skin surface of the dogs was carefully inspected in the search for lesions or 155 
scars. Particular attention was paid to the limbs, ears, nose and scrotum, since ulcerous lesions 156 
were most often found in these areas. The clinical criteria used to define “suspected leishmaniasis 157 
lesions” were: ulcerative character, long duration, and rounded, raised and indurated edges, 158 
coupled with swollen lymph node. Lesions probably induced by trauma were not considered to be 159 
Leishmania spp. infection. 160 
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Canines classified as no leishmaniasis (noL) were dogs without any sign of leishmaniasis and 161 
negative for the ELISA serological test (6).  162 
Study 2:  163 
Thirty-three dogs were submitted to a careful clinical evaluation by veterinarians from  164 
“Veterinaria del Oeste” in the city of Posadas, Province of Misiones, NE Argentina and diagnosed 165 
with VL or  no leishmaniasis (NoL) based on parasitological and serological tests and supported 166 
by clinical signs (38). We have recently found Leishmania (Leishmania) infantum as the causative 167 
agents of canine VL cases in the city of Posadas (39). 168 
Amastigotes observed on smears from aspirates were analyzed for the parasitological diagnosis 169 
of canine VL. A puncture aspiration was aseptically performed on the dogs using 2.5 ml syringes 170 
and 21-gauge needles. The aspirates were taken from enlarged lymph nodes, especially the 171 
popliteal ones. When lymph nodes could not be found, the samples were taken from the bone 172 
marrow or the spleen. A fraction from each sample obtained by aspiration or the scrapings were 173 
stained with Giemsa and observed under an optical microscope. 174 
Clinical suspicion of VL was defined by the presence of three or more of the following signs: 175 
weight loss, alopecia, lymphadenopathy, renal azotemia, onychogryphosis, hepatomegaly, and 176 
splenomegaly. Signs such as exfoliative dermatitis on the nose, tail, and ear tips were also 177 
recorded. Skin features such as periocular and generalized alopecia, hair loss, seborrhea, and 178 
depigmentation in the muzzle were recorded to note the presence of skin disease without 179 
ulceration. Asymptomatic dogs appeared completely healthy at the clinical examination (no blood 180 
counts performed). 181 
Blood samples were collected from the jugular vein and sera were kept frozen until tested. The 182 
diagnosis of canine VL was confirmed in the laboratory based on the positive results of IFAT, 183 
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antigen rk39 (Kalazar Detect™ Rapid Test, Canine, InBios International, Inc) and SNAP 184 
Leishmania (IDEXX) (40).  185 
Additionally, sera from dogs living in a VL non-endemic area (Buenos Aires Province) not 186 
presenting any clinical signs of leishmaniasis and negative by the serological evaluation were also 187 
included.  188 
 189 
Ethics statement 190 
The dog owners voluntarily requested the medical attention of their animals. Under clinical 191 
suspicion of the disease, they gave their informed consent to include the dogs in this study. The 192 
procedures were approved by the Bioethics Committee of the Faculty of Agricultural and 193 
Veterinary Sciences, the Catholic University of Salta, Argentina (No. 442837/0052. October 14, 194 
2014). 195 
 196 
Parasites 197 
Leishmania braziliensis promastigotes (MHOM/BR/75/M2903 strain) were grown in liver 198 
infusion tryptose (LIT) medium, which was prepared as follows: 5 g/l liver infusion (Sigma 2023-199 
072K1066), 5 g/l tryptose (Britania), 2 g/l glucose (Sigma), 68 mM NaCl, 5.4 mM KCl, 22 mM 200 
HPO4Na2, supplemented with 20 mg/l hemin (Sigma) and 10% (vol/vol) fetal calf serum (FCS) 201 
(Internegocios). Culture maintenance was performed by weekly passages at 26 ºC. 202 
 203 
 Leishmania braziliensis supernatant lysate  204 
Promastigotes of L. braziliensis were centrifuged for 15 min at 5000 g, re-suspended in 0.25 205 
M sucrose, 5 mM KCl containing protease inhibitors (2 µM PMSF, 5µM leupeptin, 5 µM pepstatin 206 
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and 5 µM E-64; Sigma, St. Louis, MO) and broken by three cycles of freeze-thawing and 207 
sonication by 4 cycles of 30 sec on ice. The homogenate obtained was centrifuged at 45,000 g, 208 
obtaining a supernatant fraction called F45 that was conserved at −20 °C until use. Protein 209 
concentration determination was performed by the Bradford method (BIO-RAD, Protein Assay 210 
Cat. 500-0006), using bovine serum albumin as a standard. 211 
 212 
IFAT 213 
Leishmania braziliensis promastigotes harvested during the exponential growth phase by 214 
centrifugation at 5000 g for 15 min were washed three times with 0.1 M phosphate buffered saline 215 
(PBS) pH 7.2 and re-suspended with 2% formalin solution in PBS. Formalin-treated promastigotes 216 
(1x105 parasites/field) placed in immunofluorescence glasses were fixed by heat, washed twice 217 
with PBS and finally with H2O. Sera were assayed at 1/60 dilution and added to the coverslips and 218 
incubated for 16 h at 4 ºC. As secondary antibody, anti-dog IgG (whole molecule)-FITC antibody 219 
produced in rabbit (Sigma-F4012) in 0.001% Evans blue was used and observed under a 220 
fluorescence microscope.  221 
 222 
ELISA  223 
An indirect ELISA test for antibody detection was used as described elsewhere (41). Briefly, 224 
flat polystyrene bottom plates (Nunc, Roskilde, Denmark) were sensitized with 1 µg per well of 225 
the soluble fraction of L. braziliensis (F45) promastigote lysate or with 0.2 µg per well of the full 226 
length CPB (F-CPB) and its N and C-terminal domains (N-CPB and C-CPB). Blocking was done 227 
with 3% bovine serum albumin (BSA) and 0.1% gelatin in PBS during 1 h at 37 ºC. Plates were 228 
then washed three times with 0.05% Tween in PBS. Sera were assayed at a serial dilution of 1/100 229 
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and incubated for 18 h at 4ºC. Peroxidase-conjugated immunoglobulins to dog IgG (Sigma) diluted 230 
1/25000 were used as a secondary antibody. Plates were developed by adding OPD/H2O2, 231 
incubated for 10 min in the dark and the reaction was stopped using 4N H2SO4. Optical density 232 
was read by an ELISA reader (Bio-Rad Laboratories, Hercules, CA) at 490 nm. Cutoff values were 233 
calculated using receiver operating characteristic (ROC) curves. Titers were calculated as the 234 
dilution in which the optical density (OD) obtained was equal to the mean of controls ± 2.23 SD 235 
(equivalent to 99% confidence in the one-tailed test hypothesis), where applicable. 236 
 237 
Multiple sequence alignment 238 
The amino acid sequence of the L. braziliensis CPB (XP_001562140.1), without the pro-239 
domain region (aa 1 to 124), was aligned with the sequences registered in the NCBI database as 240 
‘cpb’ or ‘cysteine proteinase b’ from other Leishmania species. Namely, L. guyanensis 241 
(ACS66748.1), L. panamensis (ABX74953.1), L. major (XP_001681135.1), L. infantum 242 
(SUZ39418.1), L. donovani (AGI92544.1), L. mexicana (CAA90236.1), L. tropica (AFN27127.1), 243 
L. aethiopica (AAZ23596.1). The multiple sequence alignment was performed and the 244 
phylogenetic tree was constructed using the ClustalW2 software tool (42). 245 
 246 
Statistics 247 
The cutoff point for optimal sensitivity and specificity, as well as the other statistical 248 
parameters, were determined using the receiver operating characteristic (ROC) curve analysis to 249 
assess ELISA F-CPB, ELISA N-CPB and ELISA C-CPB using the XL-STAT statistical 250 
software/program (Excel).  251 
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Graphs were performed using the GraphPad Prism program (version 5.0). Statistical 252 
comparisons between groups were performed using the Mann-Whitney U test. P-values of < 0.05 253 
were considered statistically significant.  254 
 255 
Results 256 
CPB and its domains in the diagnosis of canine CL  257 
Dogs from NWA had been previously checked for lesions compatible with CL and for parasite 258 
microscopic observation in stained material from lesions (6). Accordingly, sera were classified 259 
into cutaneous leishmaniasis (CL) and no leishmaniasis (NoL) sera. We analyzed 76 stored sera 260 
by the immunofluorescence antibody test (IFAT). In slides containing fixed promastigotes of 261 
Leishmania braziliensis, a cutoff value of 1/60 was established for the in-house IFAT test. Later, 262 
we analyzed the samples, finding reactivity in 98.15 % of the dogs diagnosed as CL. By contrast, 263 
18.18% of dogs without leishmaniasis was positive against promastigotes of L. braziliensis by 264 
IFAT (Fig 1). These results indicate values of Se: 98.1 and Sp: 81.8% for the IFAT test in the 265 
diagnosis of canine CL. 266 
       Titration curves were performed to determine the most appropriate concentration of the L. 267 
braziliensis antigens to be used in the ELISA experiments (data not shown). Then, an ELISA assay 268 
was performed to determine specific IgG antibodies against L. braziliensis promastigote lysate 269 
(F45), the recombinant full-length CPB (F-CPB) and its domains (N-CPB and C-CPB), 270 
respectively. Fig 2 shows that IgG specific antibodies against F45, F-CPB and its domains were 271 
significantly higher in CL than in non-leishmaniasis dogs (p˂ 0.0001).  272 
We analyzed the accuracy of the ELISA tests to correctly classify the samples as CL. As shown 273 
in Fig 3 the AUC 0.9722 (95% confidence interval 0.9372 to 1.0070), 0.9722 (CI: 0.9347 to 1.010), 274 
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0.9562 (CI: 0.9055 to 1.007), and 0.9423 (CI: 0.8831 to 1.002) were determined for F45, F-CPB, 275 
N-CPB and C-CPB, respectively. According to the traditional academic point system, all the 276 
antigens showed an AUC between 0.90-1.0, which means they were excellent ligands to correctly 277 
discriminate between the two groups (43).  278 
Interestingly, the detection of antibodies against the recombinant antigens in the ELISA 279 
matrix, showed sensitivities of 0.907, 0.944 and 0.943 for F-CPB, N-CPB and C-CPB, 280 
respectively, which were equal or close to those observed when a mixture of Leishmania antigen 281 
(F45) was used (0.944). Moreover, F-CPB presented higher specificity and predictive positive 282 
value (0.955 and 0.980) than its domains (0.909 and 0.962; and 0.913 and 0.962 for the N-CPB 283 
and C-CPB, respectively) (Table 1). Overall, these results endorse F-CPB and its domains as 284 
effective tools in the diagnosis of CL in dogs, with high sensitivity and specificity.      285 
Based on a thorough analysis of clinical and epidemiological data, CL dogs were then 286 
subdivided as follows: A: dogs bearing ulcerative lesions typical of CL; B: dogs without ulcers, 287 
living in the houses of humans or other dogs with leishmaniasis; C: dogs with atypical ulcers, 288 
living in the houses of humans with leishmaniasis; D: asymptomatic dogs living in houses with 289 
human or other dogs without leishmaniasis. Interestingly, specific antibodies against all the 290 
antigens tested were significantly higher in groups A, B and C, which corresponded to dogs that 291 
had or could have been exposed to Leishmania parasites, with respect to those observed in 292 
asymptomatic dogs (group D). Titers of specific antibodies against the recombinant proteins 293 
agreed with those observed against the parasite lysate (Fig 4). 294 
 295 
CPB and its domains in the diagnosis of VL 296 
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We then analyzed the efficiency of the different antigens in the diagnosis of VL in dogs. As 297 
shown in Fig 5, significant differences in reactivity against F-CPB and its domains were observed 298 
among dogs suffering from VL or not.  299 
The ELISA containing F-CPB exhibited the best performance compared to the other antigens 300 
tested (AUC: 0.879, 0.789 and 0.723, for F-CPB, N-CPB and C-CPB respectively). These results 301 
mean that F-CPB as a coating antigen in an ELISA assay is a good candidate for the diagnosis of 302 
VL in dogs (Fig 6). In addition, we observed higher sensitivity (Se) (93.3%) and specificity (Sp) 303 
(92.30 %) for F-CPB compared to the N- (Se: 73.3 % and Sp 76.9%) and C-terminal domains (Se: 304 
66.7 and Sp: 88.5 %) (Table 2).  305 
 306 
The CPB amino acid sequence is highly conserved among Leishmania species 307 
In order to further analyze whether CPB could be a promising antigen for the diagnosis of 308 
leishmaniasis caused by the infection of several species, the amino acid sequence of the CPB from 309 
L. braziliensis was aligned with its orthologous sequence in different Leishmania species. As 310 
shown in Fig 7, high percentages of identity sere found: 91.5% for L. guyanensis (ACS66748.1), 311 
76.1% for L. panamensis (ABX74953.1), 68.1% for L. major (XP_001681135.1), 62.8% for L. 312 
infantum (SUZ39418.1), 62.5% for L. donovani (AGI92544.1), 62.2% for L. mexicana 313 
(CAA90236.1), 61.5% for L. tropica (AFN27127.1), 61.5% for L. aethiopica (AAZ23596.1) and 314 
the CPB of L. braziliensis. These results suggest that the CPB from L. braziliensis qualifies as a 315 
good target for the diagnosis of Leishmania spp. infection caused by different species of the 316 
parasite However, an exhaustive study of the ELISA performance of the CPB of L. braziliensis in 317 
Leishmania infection caused by all the mentioned strains should be carried out in the near future.  318 
 319 
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Discussion 320 
A rapid and accurate diagnosis of Leishmania spp. infection followed by the early 321 
implementation of an effective treatment in infected individuals is essential for the control of a 322 
disease that has spread for several reasons. Domestic dogs are considered the main reservoirs of 323 
L. infantum, playing an important role in the epidemiology of VL (44, 45). The number of infected 324 
dogs in South America is estimated in millions, and there are high infection rates associated with 325 
a high risk of human disease (44-46). Although the development of sensitive molecular diagnostic 326 
techniques has improved the detection of clinically healthy infected dogs, those methods are not 327 
always available to researchers in Latin America.  328 
Immunoserological tests have evolved as useful tools in the diagnosis of leishmaniasis in dogs 329 
since the humoral response in general is intense, with high levels of specific immunoglobulins (47-330 
49).  We showed in an ELISA assay that the CPB from L. braziliensis and its domains, mainly F-331 
CPB, is a promising antigen for the diagnosis of both cutaneous and visceral clinical presentations 332 
of leishmaniasis in dogs with high sensitivity and specificity (Se: 90.7, Sp: 95.5, AUC: 0.97 and 333 
Se: 93.3, Sp 92.3, AUC: 0.88, respectively (Fig 2, 5 and Tables 1, 2). Moreover, the high 334 
sensitivity of the CPB from L. braziliensis in the diagnosis of VL (93.3%) could be explained 335 
considering the higher stimulation of the immune system in the visceral form compared to a 336 
localized cutaneous presentation (Se: 90.7). In that regard, several reports (50-52) have shown the 337 
importance of the CPB from L. infantum and L. (L.) chagasi as targets of the humoral and cellular 338 
immune response and their potential use for the diagnosis of VL in humans and dogs. 339 
Bearing in mind that the species that cause CL and VL disease are generally different, the 340 
ability of the CPB from L. braziliensis to detect the infection caused by different Leishmania 341 
strains highlights its value as a candidate for the universal diagnosis of leishmaniasis. This is also 342 
 o
n
 August 23, 2019 at CALIFO
RNIA INST O
F TECHNO
LO
G
Y
http://jcm.asm.org/
D
ow
nloaded from
 
 16 
 
supported by the conserved amino acid sequence of this antigen among several Leishmania species 343 
(Fig 7).  344 
One limitation of most serological tests is their inefficiency to detect VL in dogs during the 345 
early stages of infection. Early detection of canine VL is highly desirable in order to shorten the 346 
contact time between the infected reservoirs and the vectors. In that regard, Faria (53) has reported 347 
an ELISA for two multiepitope proteins, PQ10 and PQ20, which was able to detect Leishmania 348 
infection at earlier time points as compared with kDNA PCR-RFLP in anti-IgG and anti-IgM 349 
assays. In Fig 4, we observed that dogs without ulcers living in contact with humans with 350 
leishmaniasis (Group B) displayed a significant increase in IgG titers against F-CPB and its 351 
domains, in comparison with asymptomatic dogs (Group D). These results indicate that the CPB 352 
of L. braziliensis can be a good predictor of Leishmania spp. infection yielding significant serum 353 
IgG antibodies in the host before the onset of leishmaniasis symptoms. This hypothesis needs to 354 
be further explored in future studies. 355 
Recently, Lima (54) showed high sensitivity and specificity of an ELISA assay from a L. 356 
braziliensis kinesin-like hypothetical protein (LbHyM) for the serodiagnosis of human cutaneous 357 
and mucosal leishmaniasis. Nearly 78% similarities were found in the amino acid sequence 358 
comparison between LbHyM and the T. cruzi hypothetical protein. The strong cross-reactivity 359 
between Leishmania and T. cruzi makes their differential serodiagnosis difficult. Since the drugs 360 
used for the treatment of both parasitoses are different, an accurate diagnosis is necessary. In a 361 
preliminary study we have recently observed no cross-reactivity between T. cruzi-infected patients 362 
and the CPB of L. braziliensis, by ELISA. Additionally, sera from patients that were positive for 363 
the F-CPB from L. braziliensis and its domains did not recognize in an immunoblotting assay, T. 364 
cruzi specific antigens like cruzipain, thiol-transferase (Tc52) and the flagellar calcium-binding 365 
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protein (Tc24). By contrast, samples from patients with Chagas disease recognized all these T. 366 
cruzi antigens (data not shown).  367 
We conclude that the performance of the CPB from L. braziliensis and its domains turns them 368 
into promising antigens for the diagnosis of leishmaniasis in dogs caused by different Leishmania 369 
species. Furthermore, it must be considered that the ELISA assay, with potential application in 370 
endemic areas, could be further improved by the addition of other antigens, using different 371 
blocking reagents or different detection systems, such as streptavidin-peroxidase. The analysis of 372 
potential cross-reactivity with other co-endemic diseases and pathogens must be further 373 
investigated as the next step to validate CPB in the diagnosis of Leishmania spp. infection.  374 
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 557 
Figure Legends  558 
Figure 1. Immunofluorescence antibody test (IFAT) of dog sera from Northwestern 559 
Argentina (NWA). Dogs previously diagnosed with (A) cutaneous leishmaniasis (CL), or (B) no 560 
leishmaniasis (noL), by direct methods, epidemiological, and clinical examination were tested for 561 
their reactivity against promastigotes of L. braziliensis by an IFAT test. Fixed Leishmania 562 
braziliensis promastigotes were incubated overnight with dog sera with CL (C) and noL (D and 563 
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E); and then stained with an anti-dog IgG FITC-labeled antibody. The figures show representative 564 
images of epifluorescence (C and D) and brightfield (E) microscopy. Magnifications 40X. 565 
 566 
Figure 2.  ELISA of sera from dogs living in the Northwest of Argentina. Canines classified 567 
as diagnosed with cutaneous leishmaniasis (CL) or no leishmaniasis (NoL) were assayed for the 568 
presence of IgG antibodies against L. braziliensis: (A) promastigote lysate (F45), (B) full-length 569 
CPB, (C) N-terminal domain of the CPB and (D) C-terminal domain of the CPB. The results were 570 
expressed as the DO490 nm, and the cutoff (CO) was calculated using the ROC curve. Lines 571 
represent the mean ± S.E.M. ****˂p 0.0001. 572 
 573 
Figure 3. ROC curves for ELISAs coated with the recombinant antigens. Sera from dogs from 574 
the Northwest of Argentina were analyzed by an ELISA assay against L. braziliensis: (A) 575 
promastigote lysate (F45), (B) full-length CPB, (C) N-terminal domain of the CPB and (D) C-576 
terminal domain of the CPB. True positive rate (Sensitivity) was plotted as a function of the false 577 
positive rate (100-Specificity) for the different Leishmania antigens at different cutoff points. An 578 
area of 1 represents a perfect test while an area of 0.5 represents a worthless test. The accuracy of 579 
a diagnostic test is: 0.90-1 = excellent, 0.80-0.90 = good, 0.70-0.80 = fair, 0.60-0.70 = poor, 0.50-580 
0.60 = fail. 581 
 582 
Figure 4. ELISA test of sera from dogs living in the Northwest of Argentina. Sera were assayed 583 
for the presence of IgG antibodies against L. braziliensis promastigote lysate (F45), full -length 584 
CPB, N and C-terminal domains. Groups: A: dogs bearing ulcerative lesions typical of CL; B: 585 
dogs without ulcers, but living in the houses of humans or other dogs with leishmaniasis; C: dogs 586 
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with atypical ulcers, living in the houses of humans with leishmaniasis; D: asymptomatic dogs 587 
from endemic areas living in houses with human or other dogs without leishmaniasis. Results are 588 
expressed as the titers of specific antibodies. Titers were calculated as the dilution in which the 589 
optical density (OD) obtained was equal to the mean of controls ± 2.23 SD for each antigen. **p 590 
< 0.01 and ***p < 0 0.005 and ****p< 0.0001.  591 
 592 
Figure 5. CPB and its domains in the diagnosis of canine visceral leishmaniasis. Sera from 593 
dogs from the Northeast and center of Argentina were assayed for the presence of IgG antibodies 594 
against L. braziliensis promastigote lysate (F45); full -length CPB; N- and C-Terminal domains. 595 
Results are expressed as OD490 nm. Lines represent the mean ± S.E.M. The cutoff (CO) for the 596 
different antigens was determined using the ROC curve. *p < 0.05, **p < 0.01 and ***p< 0.0005 597 
and ****p< 0.0001.  598 
 599 
Figure 6. Diagnostic efficacy of the recombinant antigens in canine VL using ROC curves.  600 
Sera from dogs from the Northeast and center of Argentina were analyzed in an ELISA matrix 601 
against L. braziliensis: (A) promastigote lysate (F45), (B) full-length CPB, (C) N-terminal and (D) 602 
C-terminal domains of the CPB. True positive rate (Sensitivity) was plotted as a function of the 603 
false positive rate (100-Specificity) for the different Leishmania antigens at different cutoff points. 604 
An area of 1 represents a perfect test while an area of 0.5 represents a worthless test. The accuracy 605 
of a diagnostic test is: 0.90-1 = excellent, 0.80-0.90 = good, 0.70-0.80 = fair, 0.60-0.70 = poor, 606 
0.50-0.60 = fail. 607 
 608 
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Figure 7. Conservation of the amino acid sequence of cysteine proteinase B (CPB) in different 609 
Leishmania species. (A) Alignment of the CPB from L. braziliensis with its orthologous 610 
sequences from L. guyanensis (ACS66748.1), L. panamensis (ABX74953.1), L. major 611 
(XP_001681135.1), L. infantum (SUZ39418.1), L. donovani (AGI92544.1), L. mexicana 612 
(CAA90236.1), L. tropica (AFN27127.1) and L. aethiopica (AAZ23596.1). (B) Phylogenetic tree 613 
based on the amino acid sequence of the CPB in Leishmania. 614 
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Table 1.  Statistic parameters of the ELISA test against the cysteine proteinase B from L. 630 
braziliensis (CPB) and its domains for the diagnosis of CL in dogs.  631 
STATISTICS 
ANTIGEN  
F45 F-CPB N-CPB C-CPB 
Se  0.944 0.907 0.944 0.943 
Sp 0.909 0.955 0.909 0.913 
TP 51 49 51 50 
FP 2 1 2 2 
TN 20 21 20 21 
FN 3 5 3 3 
PPV 0.870 0.980 0.962 0.962 
NPV 0.962 0.808 0.870 0.875 
AUC 0.972 0.972 0.956 0.948 
 632 
Abbreviations: Se: sensitivity; Sp: specificity; TP: true positive; FP: false positive; TN: true 633 
negative; FN: false negative; PPV: positive predictive values; NPV: negative predictive values; 634 
AUC: area under the curve. 635 
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Table 2.  Statistic parameters of the ELISA test against cysteine proteinase B from L. braziliensis 637 
(CPB) and its domains for the diagnosis of VL in dogs.  638 
STATISTICS 
ANTIGEN  
F45 F-CPB N-CPB C-CPB 
Se  0.867 0.933 0.733 0.667 
Sp 1.000 0.923 0.769 0.885 
TP 13 14 11 10 
FP 0 2 6 3 
TN 26 24 20 23 
FN 2 1 4 5 
PPV 1.0 0.875 0.647 0.769 
NPV 0.929 0.960 0.833 0.821 
AUC 0.941 0.879 0.7897 0.723 
 639 
Abbreviations: Se: sensitivity; Sp: specificity; TP: true positive; FP: false positive; TN: true 640 
negative; FN: false negative; PPV: positive predictive values; NPV: negative predictive values; 641 
AUC: area under the curve. 642 
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